Moleculin Announces Grant Awarded to Polish Research Institute for Independent Clinical Trial of Annamycin in Sarcoma Lung MetastasesPRNewsWire • 02/08/21
Moleculin Signs Agreement with Catalyst Clinical Research to Begin Sarcoma TrialPRNewsWire • 02/01/21
Moleculin Announces Annamycin Receives FDA Orphan Drug Designation for Soft Tissue SarcomasPRNewsWire • 12/29/20
Moleculin Announces FDA Permission to Begin Clinical Study of Annamycin for Sarcoma Lung MetastasesPRNewsWire • 12/17/20
Moleculin To Present Antitumor Activity of Annamycin in Combination with Ara-C in AML at American Society for Hematology Annual ConferencePRNewsWire • 12/03/20
Moleculin Announces FDA Approves 3 Rare Pediatric Disease Designations for WP1066PRNewsWire • 12/01/20
Moleculin Announces New Data Demonstrating Synergistic Antitumor Activity of Annamycin Combination with Ara-C in AMLPRNewsWire • 11/19/20
Moleculin Biotech, Inc. Reports Financial Results for the Quarter Ended September 30, 2020PRNewsWire • 11/13/20
Moleculin Announces Additional Collaboration on Drug Candidate Targeting COVID-19PRNewsWire • 10/29/20
Moleculin to Participate in Panel at ROTH Capital's "COVID-19 Therapeutics in Development" Healthcare EventPRNewsWire • 10/27/20
Moleculin Announces Independent Study Validates Annamycin's Ability to Target Lung Localized TumorsPRNewsWire • 10/21/20
Moleculin Announces Additional Positive Interim Results in Adult Glioblastoma Clinical TrialPRNewsWire • 10/13/20
Moleculin Announces New Antiviral Drug Candidates Demonstrate In Vitro Activity Against HIVPRNewsWire • 10/06/20
Moleculin Announces Positive Interim Results in Pediatric Brain Tumor Phase 1 Clinical Trial at Emory UniversityPRNewsWire • 10/01/20